• Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Joseph Dowling
  • Founded:2010

CV Sciences (OTCMKTS:CVSI) Stock Price

CV Sciences (OTCMKTS:CVSI) Company Overview

CV Sciences (OTC:CVSI) operates through two segments, Specialty Pharmaceuticals, and Consumer Products. The company focuses on developing and commercialising prescription drugs utilising synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.

The company also engages in the development, manufacture, marketing, and sale of consumer products containing Hemp-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

A well-run business with great management, and a solid track record, they are one of the best placed to take advantage of the massive Hemp market currently opening up across the US. The Farm Bill of 2018 has, without doubt, lifted the tides for all companies operating in the hemp-derived CBD space, and CV Sciences is primed to take advantage of this.

CV Sciences (OTCMKTS:CVSI) Financials

More From CV Sciences...

CV Sciences CEO Joseph Dowling Writes Letter to Shareholders
CV Sciences Reports Record Revenue of $16.9 Million in Q2
The Stars Align – CV Sciences Expands With The Kroger Co
CV Sciences Stoked On Ohio Hemp Legalization
King of the Hill – THC Global Receives "Most Significant" Cannabis License in Australia
Hemp Hemp Hooray! CV Sciences Commits to 500 Acres of Hemp Production
Hemp Stocks: The Battle of the Green Giants
Reefer Gladness – Cronos, CWEB, and CVSI Publish Eye Catching Q1 2019 Results
CV Sciences Increased Retail Distribution by Over 1000 Stores in Q1
Best Pot Stocks 2019 – Your Guide to Investing in Hemp
Load More Results

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.


Joseph Dowling
CEO & Chief Financial Officer
Prior to his appointment as Chief Executive Officer of the company in May 2018, Joseph Dowling held the position of CFO with CV Sciences.

He has also held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific.
Michael J. Mona, III
President, Co-Founder & Chief Operating Officer
Michael Mona III cofounded CV Sciences and has been instrumental in developing the worldwide supply chain for hemp products.

He previously graduated from the University of San Diego with a degree in Business Administration.
Michael J. Mona, JR.
Michael J. Mona JR is the founder of CV Sciences and possesses over 30 years of senior management experience in a range of industries including real estate/construction, industrial farming, chemical processing and consumer products.

He is a recognized industry leader in hemp farming operations and chemical extraction and has established a global supply chain of hemp-derived products.